David S. Wichmann
David S. Wichmann's purchase track record
David S. Wichmann has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/15/2021 | BSX | $1.05M | +3.4% | -3.7% | -14.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Privia Health to Report Q3 2026 Results on Nov 5. Privia Health Group is scheduled to announce its third-quarter 2026 financial results on November 5. Recent coverage highlights the company's role in healthcare automation aimed at reducing administrative costs. With the stock currently trading near its support level, investors will be watching the earnings report for updates on revenue trends and cost management.
Transaction History
| BSX | ▲ Buy | Grant | 3,800 | $0 | 5/7/2026 | View on chart |
| PRVA | ▲ Buy | Grant | 8,396 | $0 | 5/21/2025 | View on chart |
| BSX | ▲ Buy | Grant | 2,081 | $0 | 5/8/2025 | View on chart |
| PRVA | ▲ Buy | Grant | 11,124 | $0 | 5/22/2024 | View on chart |
| BSX | ▲ Buy | Grant | 2,901 | $0 | 5/9/2024 | View on chart |
| PRVA | ▲ Buy | Grant | 6,189 | $0 | 8/1/2023 | View on chart |
| BSX | ▲ Buy | Grant | 3,946 | $0 | 5/4/2023 | View on chart |
| BSX | ▲ Buy | Grant | 41 | $0 | 4/3/2023 | View on chart |
| BSX | ▲ Buy | Grant | 4,877 | $0 | 5/5/2022 | View on chart |
| BSX | ▲ Buy | Grant | 2,736 | $0 | 5/5/2022 | View on chart |
| BSX | ▲ Buy | Open Market | 25,000 | $1.0M | 11/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Boston Scientific (BSX) Faces Catheter Recall Amid Valuation Debate
Boston Scientific announced a recall of 262,686 catheters because of a life‑threatening tip failure risk. The recall adds pressure as analysts note the company needs clear evidence of its turnaround to justify a better valuation. Truist Securities kept its rating but cut its price target to $51, reflecting a more cautious view. The stock has still moved higher than the broader market, indicating mixed investor reactions.
Boston Scientific (BSX) Faces Catheter Recall Amid Valuation Debate. Boston Scientific announced a recall of 262,686 catheters because of a life‑threatening tip failure risk. The recall adds pressure as analysts note the company needs clear evidence of its turnaround to justify a better valuation. Truist Securities kept its rating but cut its price target to $51, reflecting a more cautious view. The stock has still moved higher than the broader market, indicating mixed investor reactions.